Longbow Finance SA Takes $3.46 Million Position in United Therapeutics Corporation (NASDAQ:UTHR)

Key Points

• Longbow Finance SA has acquired a new stake in United Therapeutics Corporation, buying 11,226 shares valued at approximately $3.46 million in Q1, according to their Form 13F filing.
• Institutional investors own 94.08% of United Therapeutics, with other hedge funds also increasing their stakes significantly in recent quarters, indicating strong institutional interest.
• The stock has reached a 1-year high of $417.82 and reports a net margin of 40.44%, reflecting strong earnings with a recent quarterly revenue of $794.4 million, surpassing expectations.

Longbow Finance SA acquired a new stake in shares of United Therapeutics Corporation (NASDAQ:UTHR - Free Report) in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 11,226 shares of the biotechnology company's stock, valued at approximately $3,461,000.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in UTHR. Avantax Advisory Services Inc. acquired a new position in United Therapeutics during the 4th quarter worth approximately $209,000. Envestnet Portfolio Solutions Inc. grew its holdings in shares of United Therapeutics by 8.1% in the 4th quarter. Envestnet Portfolio Solutions Inc. now owns 1,082 shares of the biotechnology company's stock worth $382,000 after acquiring an additional 81 shares during the period. LPL Financial LLC grew its holdings in shares of United Therapeutics by 122.8% in the 4th quarter. LPL Financial LLC now owns 14,239 shares of the biotechnology company's stock worth $5,024,000 after acquiring an additional 7,847 shares during the period. Vanguard Group Inc. grew its holdings in shares of United Therapeutics by 0.7% in the 4th quarter. Vanguard Group Inc. now owns 4,441,823 shares of the biotechnology company's stock worth $1,567,253,000 after acquiring an additional 32,213 shares during the period. Finally, Prudential Financial Inc. grew its holdings in shares of United Therapeutics by 22.2% in the 4th quarter. Prudential Financial Inc. now owns 66,541 shares of the biotechnology company's stock worth $23,478,000 after acquiring an additional 12,104 shares during the period. 94.08% of the stock is owned by hedge funds and other institutional investors.

United Therapeutics Stock Down 0.6%

UTHR stock traded down $1.91 during midday trading on Friday, reaching $304.50. The company had a trading volume of 310,921 shares, compared to its average volume of 372,488. The stock has a 50 day moving average price of $300.01 and a 200 day moving average price of $315.85. United Therapeutics Corporation has a fifty-two week low of $266.98 and a fifty-two week high of $417.82. The firm has a market capitalization of $13.74 billion, a PE ratio of 12.15, a P/E/G ratio of 6.64 and a beta of 0.53.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last released its quarterly earnings results on Wednesday, April 30th. The biotechnology company reported $6.63 earnings per share for the quarter, beating analysts' consensus estimates of $6.29 by $0.34. The company had revenue of $794.40 million for the quarter, compared to analysts' expectations of $726.82 million. United Therapeutics had a return on equity of 19.33% and a net margin of 40.44%. The business's revenue for the quarter was up 17.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $6.17 earnings per share. Research analysts predict that United Therapeutics Corporation will post 24.48 EPS for the current year.

Insider Transactions at United Therapeutics

In related news, EVP Paul A. Mahon sold 11,000 shares of the business's stock in a transaction that occurred on Thursday, July 24th. The stock was sold at an average price of $304.11, for a total transaction of $3,345,210.00. Following the sale, the executive vice president owned 36,781 shares of the company's stock, valued at $11,185,469.91. The trade was a 23.02% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO James Edgemond sold 12,000 shares of the business's stock in a transaction that occurred on Monday, June 9th. The stock was sold at an average price of $325.37, for a total value of $3,904,440.00. Following the sale, the chief financial officer directly owned 8,118 shares in the company, valued at approximately $2,641,353.66. The trade was a 59.65% decrease in their position. The disclosure for this sale can be found here. Insiders sold 81,681 shares of company stock worth $24,628,589 in the last three months. 10.30% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

A number of research firms recently weighed in on UTHR. HC Wainwright restated a "buy" rating and issued a $425.00 price target on shares of United Therapeutics in a report on Monday, May 5th. Bank of America lowered their target price on United Therapeutics from $321.00 to $315.00 and set a "neutral" rating on the stock in a report on Wednesday, June 11th. Wells Fargo & Company reiterated an "equal weight" rating and set a $314.00 target price (down previously from $395.00) on shares of United Therapeutics in a report on Friday, April 25th. JPMorgan Chase & Co. lowered their target price on United Therapeutics from $350.00 to $330.00 and set an "overweight" rating on the stock in a report on Tuesday, July 8th. Finally, Cantor Fitzgerald started coverage on United Therapeutics in a research note on Monday, June 2nd. They set an "overweight" rating and a $405.00 price target on the stock. Four investment analysts have rated the stock with a hold rating and ten have given a buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average price target of $383.08.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.